Выпуск
CRISPR Turns Down the Bradykinin Dial
MCAT In The Car · 20 сентября 2026 г. · 6 мин
On September 8, 2026, the FDA accepted Intellia’s biologics application for lonvo-z, a one-time in vivo CRISPR therapy for hereditary angioedema, and gave it Priority Review. That matters because a single gene edit in the liver could replace lifelong attack-prevention drugs for a rare swelling disease driven by excess bradykinin. The core MCAT hook is how loss-of-function CRISPR editing of *KLKB1* lowers plasma kallikrein and slows a proteolytic cascade that opens vessels and floods tissue. The lesson and three practice questions reinforce CRISPR mechanics, enzyme cascades, capillary permeability, autosomal-dominant genetics, and how to read a randomized Phase 3 trial.